MedTrace Logo

Clinical Research on Moderately Hypofractionated Adaptive Postoperative Radiotherapy for High-Risk Endometrial Cancer

NCT07116213 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-08-11

No results posted yet for this study

Summary

1. Study Type: Single-center, single-arm, prospective study.
2. Sample Size: 20 patients with high-risk endometrial cancer were enrolled.
3. Treatment Procedure:

The existing clinical oART (Online Adaptive Radiotherapy) workflow protocol for malignant tumors used in our department was applied.

Procedures included simulation, target volume delineation, radiotherapy planning, and treatment delivery.

External beam radiation therapy (EBRT) was delivered using moderate hypofractionation.

If indicated, brachytherapy was performed after the completion of EBRT. When combined with chemotherapy, radiotherapy could be administered during chemotherapy intervals or after completion of chemotherapy.
4. Study Endpoints:

Primary Endpoint: Incidence of acute toxicity. Secondary Endpoints: 3-year failure-free survival (FFS) rate, incidence of chronic toxicity, quality of life (QoL), treatment costs, etc.

Conditions

  • Endometrial Cancer
  • Hypofractionated Dose
  • Radiotherapy, Adjuvant
  • Side Effects
  • Survival , Tumor

Interventions

RADIATION

Moderately Hypofractionated Adaptive Radiotherapy

Moderately Hypofractionated Adaptive Postoperative Radiotherapy

Sponsors & Collaborators

  • Xiaorong Hou

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-30
Primary Completion
2029-06-30
Completion
2030-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07116213 on ClinicalTrials.gov